De novo malignancy post-liver transplantation: A single center, population controlled study

Clinical Transplantation

Volumn 27, Issue 4, 2013, Pages 582-590

  Chatrath, Hemant ^a   Berman, Kenneth ^a   Vuppalanchi, Raj ^a   Slaven, James ^a   Kwo, Paul ^a   Tector, A Joseph ^a   Chalasani, Naga ^a   Ghabril, Marwan ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

de novo; Liver transplantation; Malignancy; Population control study; Standardized incidence ratio

Indexed keywords

ADULT; ARTICLE; CANCER INCIDENCE; CANCER RISK; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; FEMALE; FOLLOW UP; HEMATOLOGIC MALIGNANCY; HUMAN; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEOPLASM; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; SOLID TUMOR; STANDARDIZED INCIDENCE RATIO; UNITED STATES;

DE NOVO; LIVER TRANSPLANTATION; MALIGNANCY; POPULATION CONTROL STUDY; STANDARDIZED INCIDENCE RATIO;

ADOLESCENT; ADULT; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INDIANA; KIDNEY TRANSPLANTATION; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASMS; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; YOUNG ADULT;

EID: 84881559360     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12171     Document Type: Article

References (39)

1. Kemmer N, Safdar K, Kaiser TE, Zacharias V, Neff GW. Liver transplantation trends for older recipients: regional and ethnic variations. Transplantation 2008: 86: 104.
2. Jain A, Fiaz O, Sheikh B et al. Recurrent nonhepatic and de novo malignancies after liver transplantation. Transplantation 2009: 88: 706.
3. Pruthi J, Medkiff KA, Esrason KT et al. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl 2001: 7: 811.
4. Gruber SA, Matas AJ. Etiology and pathogenesis of tumors occurring after organ transplantation. Transplant Sci 1994: 4: 87.
5. Matas AJ, Simmons RL, Najarian JS. Chronic antigenic stimulation, herpesvirus infection, and cancer in transplant recipients. Lancet 1975: 1: 1277.
6. Penn I, Starzl TE. Malignant tumors arising de novo in immunosuppressed organ transplant recipients. Transplantation 1972: 14: 407.
7. Penn I. The problem of cancer in organ transplant recipients: an overview. Transpl Sci 1994: 4: 23.
8. Engels EA, Pfeiffer RM, Fraumeni JF Jr et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA 2011: 306: 1891.
9. Jiang Y, Villeneuve PJ, Fenton SS, Schaubel DE, Lilly L, Mao Y. Liver transplantation and subsequent risk of cancer: findings from a Canadian cohort study. Liver Transpl 2008: 14: 1588.
10. Oo YH, Gunson BK, Lancashire RJ, Cheng KK, Neuberger JM. Incidence of cancers following orthotopic liver transplantation in a single center: comparison with national cancer incidence rates for England and Wales. Transplantation 2005: 80: 759.
11. Saigal S, Norris S, Muiesan P, Rela M, Heaton N, O'Grady J. Evidence of differential risk for posttransplantation malignancy based on pretransplantation cause in patients undergoing liver transplantation. Liver Transpl 2002: 8: 482.
12. Sanchez EQ, Marubashi S, Jung G et al. De novo tumors after liver transplantation: a single-institution experience. Liver Transpl 2002: 8: 285.
13. Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Sanchez W, Gores GJ. Long-term probability of and mortality from de novo malignancy after liver transplantation. Gastroenterology 2009: 137: 2010.
14. Galve ML, Cuervas-Mons V, Figueras J et al. Incidence and outcome of de novo malignancies after liver transplantation. Transplant Proc 1999: 31: 1275.
15. Jain A, Patil VP, Fung J. Incidence of de novo cancer and lymphoproliferative disorders after liver transplantation in relation to age and duration of follow-up. Liver Transpl 2008: 14: 1406.
16. Aberg F, Pukkala E, Hockerstedt K, Sankila R, Isoniemi H. Risk of malignant neoplasms after liver transplantation: a population-based study. Liver Transpl 2008: 14: 1428.
17. Haagsma EB, Hagens VE, Schaapveld M et al. Increased cancer risk after liver transplantation: a population-based study. J Hepatol 2001: 34: 84.
18. Grant BF, Dufour MC, Harford TC. Epidemiology of alcoholic liver disease. Semin Liver Dis 1988: 8: 12.
19. Jain A, Nalesnik M, Reyes J et al. Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience. Ann Surg 2002: 236: 429; discussion 36-7.
20. Tector AJ, Fridell JA, Mangus RS et al. Promising early results with immunosuppression using rabbit anti-thymocyte globulin and steroids with delayed introduction of tacrolimus in adult liver transplant recipients. Liver Transpl 2004: 10: 404.
21. Berman K, Tandra S, Vuppalanchi R et al. Hepatic and extrahepatic cancer in cirrhosis: a longitudinal cohort study. Am J Gastroenterol 2011: 106: 899.
22. Breslow NE, Day NE. Statistical methods in cancer research. Volume II-the design and analysis of cohort studies. IARC Sci Publ 1987: 82: 1.
23. Jain AB, Yee LD, Nalesnik MA et al. Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. Transplantation 1998: 66: 1193.
24. Baccarani U, Piselli P, Serraino D et al. Comparison of de novo tumours after liver transplantation with incidence rates from Italian cancer registries. Dig Liver Dis 2010: 42: 55.
25. Collett D, Mumford L, Banner NR, Neuberger J, Watson C. Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit. Am J Transplant 2010: 10: 1889.
26. Dumortier J, Guillaud O, Adham M et al. Negative impact of de novo malignancies rather than alcohol relapse on survival after liver transplantation for alcoholic cirrhosis: a retrospective analysis of 305 patients in a single center. Am J Gastroenterol 2007: 102: 1032.
27. Jimenez C, Marques E, Loinaz C et al. Upper aerodigestive tract and lung tumors after liver transplantation. Transplant Proc 2003: 35: 1900.
28. Zanus G, Carraro A, Vitale A et al. Alcohol abuse and de novo tumors in liver transplantation. Transplant Proc 2009: 41: 1310.
29. Bellil Y, Edelman MJ. Bronchogenic carcinoma in solid organ transplant recipients. Curr Treat Options Oncol 2006: 7: 77.
30. Herrero JI, Lucena JF, Quiroga J et al. Liver transplant recipients older than 60 years have lower survival and higher incidence of malignancy. Am J Transplant 2003: 3: 1407.
31. Finkenstedt A, Graziadei IW, Oberaigner W et al. Extensive surveillance promotes early diagnosis and improved survival of de novo malignancies in liver transplant recipients. Am J Transplant 2009: 9: 2355.
32. Xiol X, Guardiola J, Menendez S et al. Risk factors for development of de novo neoplasia after liver transplantation. Liver Transpl 2001: 7: 971.
33. Herrero JI, Lorenzo M, Quiroga J et al. De Novo neoplasia after liver transplantation: an analysis of risk factors and influence on survival. Liver Transpl 2005: 11: 89.
34. Danpanich E, Kasiske BL. Risk factors for cancer in renal transplant recipients. Transplantation 1999: 68: 1859.
35. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005: 80: 883.
36. Webster AC, Craig JC, Simpson JM, Jones MP, Chapman JR. Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15, 183 recipients. Am J Transplant 2007: 7: 2140.
37. Benlloch S, Berenguer M, Prieto M et al. De novo internal neoplasms after liver transplantation: increased risk and aggressive behavior in recent years? Am J Transplant 2004: 4: 596.
38. Berenguer M, Prieto M, Bustamante M et al. Incidence of de novo neoplasms after liver transplantation. Med Clin (Barc) 1998: 111: 481.
39. van Leeuwen MT, Webster AC, McCredie MR et al. Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study. BMJ 2010: 340: c570.